HuiTai Biomedicine is a leading biotech company that develops novel therapeutics for the treatment of Fibrotic Diseases and creates TGF-β therapeutics based on the precise and targeted regulation of TGF-β signaling. HuiTai is developing novel therapeutics to address the most severe and difficult-to-treat fibrotic conditions of the lung, liver, kidney and other organs. We have created several prospective treatments for Fibrotic Diseases, such as Idiopathic Pulmonary Fibrosis (IPF), Hepatic Fibrosis, Renal Fibrosis and more deadly Fibrotic Diseases with enormous Unmet Patient Needs.